Beaufort Securities lowered shares of AstraZeneca plc (LON:AZN) to a sell rating in a research report sent to investors on Friday. The brokerage currently has GBX 3,900 ($51.44) price target on the biopharmaceutical company’s stock.

AZN has been the subject of a number of other research reports. Morgan Stanley reiterated an overweight rating and set a GBX 5,600 ($73.87) price objective on shares of AstraZeneca plc in a research report on Friday, June 23rd. Deutsche Bank AG reiterated a buy rating on shares of AstraZeneca plc in a research report on Monday, May 22nd. Shore Capital reiterated a sell rating on shares of AstraZeneca plc in a research report on Thursday, May 4th. Barclays PLC reiterated an overweight rating and set a GBX 6,000 ($79.15) price objective on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, Liberum Capital reiterated a buy rating and set a GBX 5,500 ($72.55) price objective on shares of AstraZeneca plc in a research report on Wednesday, June 14th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of GBX 5,046.95 ($66.57).

AstraZeneca plc (AZN) opened at 4571.00 on Friday. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The firm has a 50-day moving average of GBX 5,140.37 and a 200-day moving average of GBX 4,864.62. The firm’s market cap is GBX 57.87 billion.

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Cut to Sell at Beaufort Securities” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/astrazeneca-plc-azn-cut-to-sell-at-beaufort-securities/1464792.html.

The business also recently declared a dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be given a dividend of GBX 68.90 ($0.91) per share. This represents a yield of 1.35%. The ex-dividend date is Thursday, August 10th.

In related news, insider Nazneen Rahman purchased 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. The shares were purchased at an average cost of GBX 4,370 ($57.64) per share, with a total value of £1,704.30 ($2,248.12).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.